Voya Investment Management LLC Sells 163,083 Shares of Natera, Inc. $NTRA

Key Points

• Voya Investment Management LLC reduced its stake in Natera, Inc. by 36.4% in Q1, owning approximately 0.21% of the company, valued at $40.33 million.
• Natera reported a loss per share of $0.74 for the last quarter, missing estimates, but achieved a 32.2% increase in year-over-year revenue, totaling $546.6 million.
• Institutional investors own a significant majority of Natera, with approximately 99.90% of its stock, reflecting strong interest from the investment community.

Voya Investment Management LLC lowered its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 36.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 285,197 shares of the medical research company's stock after selling 163,083 shares during the period. Voya Investment Management LLC owned approximately 0.21% of Natera worth $40,330,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of NTRA. Price T Rowe Associates Inc. MD raised its position in shares of Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. Nuveen LLC bought a new stake in Natera during the 1st quarter worth approximately $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Natera by 140.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock worth $177,298,000 after acquiring an additional 732,156 shares during the period. JPMorgan Chase & Co. increased its holdings in Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after acquiring an additional 660,538 shares during the period. Finally, SG Americas Securities LLC increased its holdings in Natera by 8,233.5% during the 1st quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock worth $56,270,000 after acquiring an additional 393,149 shares during the period. Institutional investors own 99.90% of the company's stock.

Natera Stock Up 1.1%

Shares of Natera stock traded up $1.87 during trading on Thursday, reaching $177.30. The company's stock had a trading volume of 282,535 shares, compared to its average volume of 1,450,254. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $183.00. The company has a market cap of $24.33 billion, a price-to-earnings ratio of -92.57 and a beta of 1.68. The firm's 50-day moving average is $156.05 and its two-hundred day moving average is $154.52.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. During the same period last year, the company posted ($0.30) EPS. Natera's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In other Natera news, insider John Fesko sold 678 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total transaction of $105,401.88. Following the completion of the sale, the insider owned 152,747 shares of the company's stock, valued at $23,746,048.62. This represents a 0.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 5,079 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $166.53, for a total transaction of $845,805.87. Following the sale, the chief executive officer directly owned 158,514 shares of the company's stock, valued at $26,397,336.42. The trade was a 3.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,423 shares of company stock worth $8,459,656 over the last ninety days. 5.63% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Cowen reaffirmed a "buy" rating on shares of Natera in a report on Friday, August 8th. Stephens reaffirmed an "overweight" rating and set a $183.00 target price on shares of Natera in a report on Friday, August 15th. Barclays reaffirmed an "overweight" rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Morgan Stanley reaffirmed an "overweight" rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Finally, Piper Sandler reissued an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $194.00.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.